Manuel Neves1, Fernanda Trigo2, Bergantim Rui2, Cristina João1, Paulo Lúcio1, Neves Mariana3, João Mendes4, Hugo Pedrosa5,6, Catarina Geraldes7. 1. Hemato-Oncology Unit, Hematology Department, Clinical Center of the Champalimaud Center for the Unknown, Lisbon, Portugal. 2. Hematology Department, Centro Hospitalar S. João, Porto, Portugal. 3. IQVIA Solutions Portugal, Lisbon, Portugal. 4. Janssen Portugal, Lisbon, Portugal. 5. IQVIA Solutions Portugal, Lisbon, Portugal. hugo.pedrosa@iqvia.com. 6. Lagoas Park, Edifício 3, Piso 3 Porto Salvo, 2740-266, Oeiras, Portugal. hugo.pedrosa@iqvia.com. 7. Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Abstract
BACKGROUND: Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific economic data at the country level remain scarce. OBJECTIVE: This study assesses the burden and cost of MM in Portugal from the perspective of the National Health Service (NHS) to support the definition of health policies, resource allocation and patient care. METHODS: Developed by the Portuguese Multiple Myeloma Group, this study considers the most recent available data. Burden of disease was measured using disability-adjusted life-years (DALYs). The cost of MM was estimated using a prevalence-based model that estimated direct costs for the NHS considering all costs associated with diagnosis, hospitalizations, surgeries, emergency visits, medical appointments, drugs and transportation. Costs were quantified based on the diagnosis-related group funding price, except for drug usage, which was calculated using the average hospital product stock price. RESULTS: The burden of disease attributable to MM for 2018 was estimated at 8931 DALYs: 8570 resulting from premature deaths and 361 from disability. Average yearly direct costs per patients with MM amounted to €31,449 (year 2018 values). Total direct costs are estimated at €61 million per year. CONCLUSIONS: The mortality rate in MM means that most DALYs are due to years of life lost rather than years lost due to disability. This study generates comprehensive data on the burden and cost of MM in Portugal and provides updated insights into the costs associated with the management of MM.
BACKGROUND:Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific economic data at the country level remain scarce. OBJECTIVE: This study assesses the burden and cost of MM in Portugal from the perspective of the National Health Service (NHS) to support the definition of health policies, resource allocation and patient care. METHODS: Developed by the Portuguese Multiple Myeloma Group, this study considers the most recent available data. Burden of disease was measured using disability-adjusted life-years (DALYs). The cost of MM was estimated using a prevalence-based model that estimated direct costs for the NHS considering all costs associated with diagnosis, hospitalizations, surgeries, emergency visits, medical appointments, drugs and transportation. Costs were quantified based on the diagnosis-related group funding price, except for drug usage, which was calculated using the average hospital product stock price. RESULTS: The burden of disease attributable to MM for 2018 was estimated at 8931 DALYs: 8570 resulting from premature deaths and 361 from disability. Average yearly direct costs per patients with MM amounted to €31,449 (year 2018 values). Total direct costs are estimated at €61 million per year. CONCLUSIONS: The mortality rate in MM means that most DALYs are due to years of life lost rather than years lost due to disability. This study generates comprehensive data on the burden and cost of MM in Portugal and provides updated insights into the costs associated with the management of MM.
Authors: P Moreau; J San Miguel; P Sonneveld; M V Mateos; E Zamagni; H Avet-Loiseau; R Hajek; M A Dimopoulos; H Ludwig; H Einsele; S Zweegman; T Facon; M Cavo; E Terpos; H Goldschmidt; M Attal; C Buske Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo Journal: Haematologica Date: 2015-10 Impact factor: 9.941
Authors: S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar Journal: Leukemia Date: 2013-10-25 Impact factor: 11.528
Authors: Antoine Bessou; Xavier Colin; Julie De Nascimento; Will Sopwith; Shannon Ferrante; Boris Gorsh; Benjamin Gutierrez; Leah Sansbury; Jenny Willson; Sandhya Sapra; Prani Paka; Feng Wang Journal: Eur J Health Econ Date: 2022-05-25
Authors: Jacopo Garlasco; Mario Cesare Nurchis; Valerio Bordino; Martina Sapienza; Gerardo Altamura; Gianfranco Damiani; Maria Michela Gianino Journal: Int J Environ Res Public Health Date: 2022-04-16 Impact factor: 4.614